| Active substance | Ivosidenib |
| Holder | Servier Benelux |
| Status | Running |
| Indication | Monotherapy for the treatment of adult patients with acute myeloid leukemia (AML) and an isocitrate dehydrogenase-1 (IDH1) R132 mutation not responding to initial induction therapy or with relapsed disease after initial induction therapy who are no longer a candidate for intensive chemotherapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 18/06/2026 |